Boston Scientific Corporation, a Marlborough, Massachusetts-based interventional medical devices manufacturer, in a recent press release statement on Monday, Mar. 11th 2019, announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association, to be held in Lisbon, Portugal, from Sunday, Mar. 17th to Mar. 19th 2019 at the Lisbon Congress Center.
At the EHRA congress gathering, following two late-breaking clinical trials will be presented:
- AF-FICIENT I outcomes, a prospective, multicenter, single-arm trial assessing the safety and efficacy of the LUMINIZE™ Radiofrequency (RF) Balloon Catheter for AF (Atrial Fibrillation) treatment.
- New data on the temporal association of atrial fibrillation (AF) with device-based heart failure status from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study.
According to Dr. Kenneth Stein, Sr. VP and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific, the corporation is especially looking forward to the first ever presentation of data showcasing the performance of Boston Scientific’s one of the new single-shot ablation technologies, the LUMINIZE RF Balloon Catheter, for the treatment of AF. The performance data along with the data showing the relationship between AF and worsening heart failure detected by the corporation’s multi-sensor HeartLogic Heart Failure Diagnostic will correctly demonstrate Boston Scientific’s commitment to providing personalized patient care for patients with cardiac rhythm disorders and heart failure.